会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • 1,4:3,6-DIANHYDROMANNITOL DERIVATIVES AND USE THEREOF
    • 1,4:3,6-DIANHYDROMANNITOL衍生物及其
    • WO2007121883A2
    • 2007-11-01
    • PCT/EP2007003332
    • 2007-04-05
    • ANALYTICON DISCOVERY GMBHMUELLER-KUHRT LUTZSCHIEWE HAJOSCHUNK STEFANWALDMANN HERBERTPRINZ HEINOSCHWALBE HARALDSAXENA KRISHNA
    • MUELLER-KUHRT LUTZSCHIEWE HAJOSCHUNK STEFANWALDMANN HERBERTPRINZ HEINOSCHWALBE HARALDSAXENA KRISHNA
    • C07H19/02A61K31/7042A61P35/00
    • C07H19/02C07D493/04
    • The invention relates, amongst other things, to the use of 1,4:3,6-dianhydromannitol derivatives of formulae (Ia) - (Id) where R1 is a group selected from: (i) substituted or unsubstituted tetrazoyl; (ii) substituted or unsubstituted triazoyl; (iii) substituted or unsubstituted thiophen-2-yl-acetylamino; (iv) substituted or unsubstituted pyrimidin-2-ylamino and R2, for compounds of formulae (Ia) and (Ic), is NHR3, where R3 is a group selected from (i) H; (ii) alkyl or cycloalkyl; (iii) COR' with R' selected from alkyl, heteroaryl, aryl or alkylcarboxylic acid; (iv) CONR'R" with R' and R" independently selected from H, alkyl, cycloalkyl, heteroaryl or aryl; (v) CSNR'R" with R' and R" independently selected from H, alkyl, cycloalkyl, heteroaryl or aryl; (vi) SO2R' with R' selected from alkyl, cycloalkyl, heteroaryl or aryl; or R2, in compounds of formulae (Ib) and (Id), is OR4, where R4 is a group selected from (vii) alkyl, cycloalkyl, heteroaryl or aryl; (viii) CONR'R" with R' and R" independently selected from H, alkyl, cycloalkyl, heteroaryl or aryl as therapeutic agents.
    • 本发明涉及到u。 一。 使用的1,4:下式的3,6- Dianhydromannitol-衍生物(IA) - (Id)的其中R 1是选自下组的基团:取代的(i)或未被取代的四唑基; (二)取代的或未取代的三唑基; (ⅲ)被取代或未被取代的噻吩-2-基 - 乙酰基氨基; (四)取代或未取代的嘧啶-2-基氨基; 和R2为式(Ia)化合物和(Ic)代表NHR 3,其中R 3是选自下组的基团(OH,(ⅱ)烷基或环烷基;(ⅲ)COR1其中R选自包含烷基的组中选择”, 杂芳基,芳基或烷基羧酸,(IV)CONR'R“其中R 1和R”独立地选自H,烷基,环烷基,杂芳基或芳基;(v)的CSNR'R“其中R“和R”是独立选择的 选自H,烷基,环烷基,杂芳基或芳基;(ⅵ)SO 2 R“与R 1选自包括烷基,环烷基,杂芳基,或芳基;或R 2的式(Ib)和(Id)化合物中代表OR4,其中 R 4是选自(VII)烷基,环烷基,杂芳基或芳基中选出的基团;(ⅷ)CONR'R“其中R“和R”选自H,烷基,环烷基,杂芳基或芳基是独立选择的;作为 治疗药物。